Literature DB >> 35707698

Cisplatin and paclitaxel co-delivery nanosystem for ovarian cancer chemotherapy.

Qiaoying Wang1, Changqiang Wu2, Xiaoting Li1, Dixiao Yang1, Liangjun Shi1.   

Abstract

We have designed and developed an effective drug delivery system using biocompatible polymer of poly (ethylene glycol)-polyaspartic acid (mPEG-PAsp) for co-loading the chemotherapy drugs paclitaxel (PTX) and cisplatin (CP) in one nano-vehicle. This study aimed to improve the anti-cancer efficacy of combinations of chemotherapy drugs and reduce their side effects. mPEG-PAsp-(PTX/Pt) nano-micelles disperse well in aqueous solution and have a narrow size distribution (37.8 ± 3.2 nm) in dynamic light scattering (DLS). Drug release profiles found that CP released at pH 5.5 was significantly faster than that at pH 7.4. MPEG-PAsp-(PTX/Pt) nano-micelles displayed a significantly higher tumor inhibitory effect than mPEG-PAsp-PTX nano-micelles when the polymer concentrations reached 50 μg/mL. Our data indicated that polymer micelles of mPEG-PAsp loaded with the combined drug exert synergistic anti-tumor efficacy on SKOV3 ovarian cells via different action mechanisms. Results from our studies suggested that mPEG-PAsp-(PTX/Pt) nano-micelles are promising alternatives for carrying and improving the delivery of therapeutic drugs with different water solubilities.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  co-delivery nanosystem; combination chemotherapy; drug delivery; ovarian cancer; paclitaxel

Year:  2021        PMID: 35707698      PMCID: PMC8240646          DOI: 10.1093/rb/rbab015

Source DB:  PubMed          Journal:  Regen Biomater        ISSN: 2056-3426


  32 in total

Review 1.  Polypeptides and 100 years of chemistry of alpha-amino acid N-carboxyanhydrides.

Authors:  Hans R Kricheldorf
Journal:  Angew Chem Int Ed Engl       Date:  2006-09-04       Impact factor: 15.336

2.  Nanoparticle-Mediated Mitochondrial Damage Induces Apoptosis in Cancer.

Authors:  Abhik Mallick; Piyush More; Muhammed Muazzam Kamil Syed; Sudipta Basu
Journal:  ACS Appl Mater Interfaces       Date:  2016-05-18       Impact factor: 9.229

Review 3.  Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report.

Authors:  Serge Mignani; Maria Bryszewska; Barbara Klajnert-Maculewicz; Maria Zablocka; Jean-Pierre Majoral
Journal:  Biomacromolecules       Date:  2014-12-11       Impact factor: 6.988

Review 4.  Paclitaxel and its formulations.

Authors:  Anil K Singla; Alka Garg; Deepika Aggarwal
Journal:  Int J Pharm       Date:  2002-03-20       Impact factor: 5.875

5.  Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment.

Authors:  Lili Wang; Changying Shi; Forrest A Wright; Dandan Guo; Xu Wang; Dongliang Wang; Richard J H Wojcikiewicz; Juntao Luo
Journal:  Cancer Res       Date:  2017-04-10       Impact factor: 12.701

Review 6.  Co-delivery of chemotherapeutics and proteins for synergistic therapy.

Authors:  Chaoliang He; Zhaohui Tang; Huayu Tian; Xuesi Chen
Journal:  Adv Drug Deliv Rev       Date:  2015-11-06       Impact factor: 15.470

Review 7.  Valproic acid as a promising agent to combat Alzheimer's disease.

Authors:  Xiu-Zhen Zhang; Xue-Juan Li; Hong-Yu Zhang
Journal:  Brain Res Bull       Date:  2010-01-15       Impact factor: 4.077

8.  First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients.

Authors:  A Romanini; L Tanganelli; F Carnino; A Fanucchi; R Lionetto; S Pastorino; S Cosio; A Gadducci; P F Conte
Journal:  Gynecol Oncol       Date:  2003-06       Impact factor: 5.482

Review 9.  Drug combinations with proteasome inhibitors in antitumor therapy.

Authors:  Laura Gatti; Valentina Zuco; Nadia Zaffaroni; Paola Perego
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome.

Authors:  Tsuyoshi Ohta; Masanori Isobe; Toshifumi Takahashi; Maki Saitoh-Sekiguchi; Teiichi Motoyama; Hirohisa Kurachi
Journal:  Anticancer Res       Date:  2009-11       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.